SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
Stroke is a leading cause of disability and mortality globally. With population aging, ischemic stroke (80% of cases) has become China's primary cause of adult disability. Sodium-dependent glucose transporters 2 inhibitors SGLT2i demonstrate cardiovascular protection beyond glycemic control, even in patients without diabetes.
Preclinical studies suggest neuroprotective effects via improving cerebral glucose metabolism, anti-inflammatory/antioxidant actions, and reducing neuronal apoptosis. Therefore, the investigators aim to evaluate whether SGLT2i could improve 3-month functional outcomes (mRS scores) in AIS patients compared to standard care.
Phase:
PHASE3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University